<![CDATA[BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma]]>

Phase 1positiveBMS-986453Positive

AI Analysis

Summary

BMS-986453, a BCMA/GPRC5D CAR T-cell therapy, demonstrated favorable safety and high response rates in a Phase 1 first-in-human trial for relapsed/refractory multiple myeloma.

Clinical Trial Data

Phase

Phase 1

Primary Endpoint

Met

Outcome Details

Favorable safety profile and high response rates

Importance:6/10

Sentiment:

0.70

CAR-TMultiple MyelomaBCMAGPRC5DFirst-in-humanRelapsed/Refractory

Related Companies

$BMY

Read the original article

Published by Cancer Network on September 29, 2026 7:00 PM

Read Original